Occam Recruits AIDD Pioneer Kim Branson to Cradle Advisory Board
In June 2026, Occam Global recruited Kim Branson, PhD, to the Advisory Board of Cradle, a leading AI-powered protein engineering platform company.
Branson is widely regarded as one of the foremost leaders in AI for drug discovery and development. As Chief AI Officer at GSK, he leads a global organization of more than 150 engineers and machine learning researchers applying AI across target discovery, human genetics, causal machine learning, and clinical development. Prior to GSK, he served as Head of AI for Early Clinical Development at Genentech.
Over the course of his career, Branson has been at the forefront of translating advances in machine learning into real-world scientific and clinical impact. He holds a PhD in Computational Drug Design from the University of Melbourne and studied Microbiology, Immunology, and Biochemistry as an undergrad at the University of Adelaide.
As the convergence of AI and biology continues to transform drug discovery, Branson's appointment brings world-class technical expertise and strategic insight to Cradle's advisory board.
.jpg)
DISCOVER OCCAM GLOBAL
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies.
Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.